What Are Semax and Noopept? Nootropic Entries
Peptides related to cognition and mood.
An ACTH fragment; BDNF/NGF-related.
| Attribute | Value |
|---|---|
| Spec code | SX10 / SX5 (SEM) |
| Specs | 10mg / 5mg |
| Mechanism | ACTH 4–10 fragment, upregulates BDNF/NGF, modulates monoamines |
| Scenario | Focus, discomfort related to insufficient cerebral blood supply |
Compare mechanistically with Selank and BRAIN20 to understand how the pathways divide the work. Common application scenarios include Brain Fog and Focus.
Selank
Section titled “Selank”A GABAergic modulation-related peptide.
| Attribute | Value |
|---|---|
| Spec code | SL10 / SL5 (SEL) |
| Specs | 10mg / 5mg |
| Mechanism | Allosteric modulation of the GABA system, affecting norepinephrine |
| Scenario | Anxiety and tension, mood stabilization, relatively non-sedating |
Compare mechanistically with Semax and BRAIN20 to understand how the pathways divide the work. Common application scenarios include Stress and Anxiety.
Noopept
Section titled “Noopept”A nootropic dipeptide; cholinergic and LTP.
| Attribute | Value |
|---|---|
| Spec code | NOOP30 / NOOP10 |
| Specs | 30mg / 10mg |
| Mechanism | Piracetam-like analog, enhances hippocampal cholinergic function and LTP |
| Scenario | Memory consolidation, cognitive slowing |
Compare mechanistically with Dihexa and Semax to understand how the pathways divide the work.
Dihexa
Section titled “Dihexa”A synaptogenesis research peptide.
| Attribute | Value |
|---|---|
| Spec code | DHX10 / DHX5 |
| Specs | 10mg / 5mg |
| Mechanism | HGF/c-Met pathway synaptogenesis (mainly animal cognitive models) |
| Scenario | Neural network repair research direction |
Compare mechanistically with Noopept and Cerebrolysin to understand how the pathways divide the work.
Cerebrolysin
Section titled “Cerebrolysin”A brain protein hydrolysate; neurotrophic-related.
| Attribute | Value |
|---|---|
| Spec code | CH10ML |
| Specs | 10ml |
| Mechanism | Synergy of multiple neurotrophic-related peptide fragments |
| Scenario | Cerebrovascular sequelae, functional recovery after traumatic brain injury |
Compare mechanistically with Semax and Dihexa to understand how the pathways divide the work.
Action Target Comparison
Section titled “Action Target Comparison”| Target | Look at first | Related |
|---|---|---|
| Focus / cerebral blood supply | Semax | BRAIN20 |
| Anxiety without sedation | Selank | BRAIN20 |
| Memory consolidation | Noopept | With Semax |
| Synapse repair research | Dihexa | Frontier, evidence from animal models |
| Brain injury rehabilitation | Cerebrolysin | History of neurological use |
Related Research (PubMed)
Section titled “Related Research (PubMed)”| Reference | Highlights |
|---|---|
| Selank/Semax functional connectome (PMID: 32342318) | Resting-state brain functional connectivity research |
| Semax in acute ischemic stroke (PMID: 11517472) | Clinical and electrophysiological observations |
| Semax and SCI recovery mechanisms (PMID: 40692165) | Animal/mechanistic |
| Orthopedic therapeutic peptide review (PMID: 41490200) | Includes neuroactive peptides such as selank/semax |
Noopept Clinical
Section titled “Noopept Clinical”| Reference | Highlights |
|---|---|
| Mild cognitive impairment EEG study (PMID: 19008801) | EEG and cognitive dynamics |
| Post-stroke mild cognitive impairment (PMID: 22500312) | Clinical observations |
Noopept evidence comes mostly from regional clinical reports; large-scale multicenter RCTs remain limited.
Regulatory and Usage Overview
Section titled “Regulatory and Usage Overview”| Entry | Common status |
|---|---|
| Semax / Selank | Some countries (e.g. Russia) have a history of clinical use; most markets regulate them as drugs or research substances |
| Noopept | Discussed in some regions as a drug/dietary ingredient; international regulation varies |
| Cerebrolysin | History of neurological indication use in many countries |
| Dihexa | Research compound, not an approved drug |
Registration status varies by market; check the local drug regulatory database before use.
Cognitive Goals and Triage
Section titled “Cognitive Goals and Triage”For cognitive complaints (focus, memory, brain fog), subtract before you add: sleep, mood, and metabolic baselines outweigh any research peptide.
Sleep, Mood, and Baselines First
Section titled “Sleep, Mood, and Baselines First”Short-term cognitive fluctuation is most often driven by sleep debt and stress load rather than “a missing peptide”. Baseline screening starts with Deep Sleep and Stress and Anxiety; the differential entry point for brain fog and focus is Focus and Brain Fog.
The Boundary with Medication
Section titled “The Boundary with Medication”Objects such as Semax and Selank sit at the boundary between research and clinical use in some regions, and interaction data with neurological medications are limited; people on long-term medication should discuss with a physician before stacking anything. This site provides no prescribing advice.
This page is for research and teaching reference only and does not constitute medical advice or dosing guidance; centrally acting objects should be used under a physician’s guidance.
Related Reading
Section titled “Related Reading”Safety Boundaries and Limitations
Section titled “Safety Boundaries and Limitations”Cognitive effects are confounded by sleep, mood, and expectancy effects. Central peptides may interact with neurological medications.
Practical workflow and quality control: before using or comparing an ingredient, see reconstitution, storage, COA, and administration routes; operating standards in Peptide Basics.